Uptake of robot-assisted radical prostatectomy in the Netherlands

There is an interesting article just published in Social Science & Medicine that addresses the social, “emotive”, and other drivers for uptake of da Vinci robot-assisted radical prostatectomy over the past few years in the Netherlands. … READ MORE …

FDA has questions about Ablatherm HIFU device

According to a report on the Bloomberg News web site, the FDA’s reviewers appear to be less than enthusiastic about the effectiveness and safety data submitted by EDAP TMS to support approval of the Ablatherm device for use of high-intensity focused ultrasound (HIFU) for the treatment of low-risk forms of prostate cancer. … READ MORE …

Robot-assisted versus open radical cystectomy: no clear signs of immediate benefit

Many readers of this blog have probably heard or read the reports like this one on the CBS Evening News or this one on the Reuters web site that there were no significant short-term (perioperative) differences in outcome between robot-assisted radical cystectomy (complete removal of the bladder) and the older open surgical procedure. … READ MORE …

NICE approves coverage for enzalutamide by NHS

The National Institute for Health and Care Excellence (NICE) has issued final approval for coverage of treatment with enzalutamide (Xtandi) for men with metastatic, castrated-resistant prostate cancer (mCRPC) who have already received prior treatment with docetaxel-based chemotherapy. … READ MORE …

The potential promise of BLZ-100 or “tumor paint”

There has been a lot of media interest in the past couple of weeks in a new technology that may be very helpful in enhancing the visibility of cancerous tissues and the ability to differentiate visually between cancerous and healthy tissue. … READ MORE …

Canadian scientists to get major grant from Movember Foundation

According to media reports, the Movember Foundation has just awarded $4.7 million to “a team of Canadian scientists” to support the development of molecular diagnostic tests that could be used to guide the treatment of prostate cancer. … READ MORE …

Quality of life after standard therapies for localized prostate cancer

Assessment of patient quality of life (QoL) after standard forms of treatment for localized prostate cancer is difficult for many reasons — not least because there is no real agreement among members of the research community about the best ways to measure QoL or patient satisfaction after treatment. … READ MORE …

Is baseline free serum T a factor in appropriate management on active surveillance?

Analysis of data from a cohort of 154 Chilean men with prostate cancer, all being monitored on active surveillance, suggests that free serum testosterone levels (but not total testosterone levels) may be able to help to predict which of these men will go on to need active treatment. … READ MORE …

ART or SRT in high-risk patients post-surgery?

As many of our regular readers will know, there is no clear answer to the question whether, among men at elevated risk of progressive disease after first-line surgery, it is better to have adjuvant radiation therapy (ART) within a few months of surgery or to wait until salvage radiation therapy (SRT) is clearly advisable. … READ MORE …

No 15-year survival benefit associated with primary ADT in older men

In another paper just published on-line in JAMA Internal Medicine this week, the authors have provided additional data indicating — once again — the lack of any value of primary androgen deprivation therapy (ADT) in the management of early-stage, localized prostate cancer among older patients. … READ MORE …

Physicians’ attitudes and the management of low-risk prostate cancer in older American men

According to newly published data in JAMA Internal Medicine and discussed on the Reuters web site today, “physician characteristics may play a larger role than disease characteristics when it comes to how patients with low-risk prostate cancer are initially treated.” This won’t come as a big surprise to most experienced prostate cancer advocates. … READ MORE …

Sociodemographics and 10-year prostate cancer survival data

The issue of sociodemographic inequality in the delivery of cancer care is well understood in America — and we don’t really know how to provide a high quality of care to those who are disadvantaged by economic factors, racial factors, or other demographic factors (such a rural vs. urban issues of access to care). … READ MORE …

If you’re already depressed, you may need help to make good decisions

In a rather less that surprising finding, a new paper in the Journal of Clinical Oncology reports that men with existing depressive disorders at the time of diagnosis with prostate cancer “are less likely to undergo definitive treatment and experience worse overall survival.” … READ MORE …

Antioxidants and cancer: do they, could they really work?

For much of the past 30 years or so there has been a great deal of effort to try to prove that antioxidants — and most specifically dietary antioxidants like some vitamins — can be used to either prevent the onset of certain cancers or to prevent the progression of early-stage cancers after a diagnosis. … READ MORE …

Will CART-type treatments be usable to treat prostate cancer?

Many of our readers may be aware of what is known as “chimeric antigen receptor T-cell” therapy (often known as CART), and its development by Carl June and colleagues at the University of Pennsylvania over the past few years. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,119 other followers